Protagenic Therapeutics Reports Reduced Net Loss and Strategic Organizational Changes

Protagenic Therapeutics, Inc. reported a net loss of $963,616 for the three months ended June 30, 2026, a significant reduction from the $5,057,523 loss recorded in the same period the previous year. This improvement is attributed to a decrease in total operating expenses, which fell by 20% to $961,247, down from $1,208,374 in the prior year. The reduction in expenses was primarily driven by a substantial decrease in research and development costs, which dropped to $109,925 from $394,112, reflecting the deconsolidation of Phytanix Bio following the unwind of the merger in February 2026.

The company's total assets decreased to $2,796,006 as of June 30, 2026, down from $3,650,370 at the end of the previous fiscal period. Current assets also saw a decline, with cash in the bank falling to $565,985 from $1,509,178. The company reported a working capital deficit of $362,743, compared to a working capital surplus of $511,107 as of March 31, 2026. This shift indicates a tightening liquidity position, which management acknowledges may necessitate raising additional capital to sustain operations beyond the third quarter of 2026.

In terms of operational developments, Protagenic has streamlined its workforce, currently employing two full-time staff members and three paid consultants. The company is focused on advancing its lead drug candidate, PT00114, which is in the clinical trial phase for treating anxiety and depression. The anticipated timeline for clinical milestones includes the initiation of a Phase Ib study in Q4 2026 and a Phase IIa study in Q2 2027, with results expected to be publicly available by Q3 2027.

Strategically, Protagenic has undergone significant organizational changes, including the unwind of its merger with Phytanix Bio, which was finalized on February 17, 2026. This decision was made following a settlement agreement related to litigation involving the merger. The unwind has allowed Protagenic to refocus on its core operations and drug development efforts without the complexities associated with the previous merger. The company is actively exploring partnerships and financing options to bolster its liquidity and support ongoing research and development activities.

Looking ahead, Protagenic's management remains cautious but optimistic about the future. They are exploring various avenues for raising capital, including potential partnerships with established companies in the neurobiology field. However, the company has acknowledged that it does not currently have committed sources of additional capital, which raises concerns about its ability to continue operations if funding is not secured in a timely manner. The outlook remains contingent on the successful advancement of its clinical programs and the ability to generate revenue from its drug candidates in the coming years.